文献速递肿瘤 PET/CT放射性药物与辐射防护

CT、MRI与F-18 FDG PET/CT用于口腔鳞状细胞癌初始N分期的成本效果比较

Comparison of CT, MRI, and F-18 FDG PET/CT for initial N-staging of oral squamous cell carcinoma: a cost-effectiveness analysis.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2022-05-24

本研究在美国医疗体系下构建决策模型,比较CT、MRI与全身F-18 FDG PET/CT用于口腔鳞状细胞癌初始N分期的成本效果。基础方案总成本CT为239,628美元、MRI为240,001美元、PET/CT为239,131美元,效果分别为5.29、5.30、5.32 QALYs;PET/CT相对MRI和CT均为最具成本效果的策略。

要点

  • 在美国医疗体系下,PET/CT用于口腔鳞状细胞癌初始N分期的成本效果优于MRI和CT。
  • 基础方案总成本PET/CT为239,131美元,低于CT的239,628美元和MRI的240,001美元。
  • 基础方案效果PET/CT为5.32 QALYs,高于CT的5.29 QALYs和MRI的5.30 QALYs。

核心结论

  • 与美国医疗体系下MRI和CT相比,F-18 FDG PET/CT是口腔鳞状细胞癌初始N分期最具成本效果的策略。
  • 尽管常规使用较少,全身PET/CT和MRI在口腔鳞状细胞癌N分期中均为具有成本效果的模态。
  • 作者认为,基于这些发现,可建议在口腔鳞状细胞癌初始分期中实施PET/CT,以帮助降低成本并提高效果。

研究设计与样本

  • 本研究构建决策模型,采用质量调整生命年(QALYs)和不同影像策略的总成本,针对不同疾病状态进行马尔可夫转换模拟。
  • 比较的影像策略包括头颈胸部CT、颈部MRI联合胸部CT、以及全身F-18 FDG PET/CT。
  • 输入参数来自文献,支付意愿阈值设为100,000美元/QALY;对诊断参数和成本进行确定性敏感性分析,并采用蒙特卡罗建模进行概率敏感性分析。

主要发现

  • 基础方案总成本:CT为239,628美元,MRI为240,001美元,F-18 FDG PET/CT为239,131美元。
  • 基础方案效果:CT为5.29 QALYs,MRI为5.30 QALYs,F-18 FDG PET/CT为5.32 QALYs。
  • F-18 FDG PET/CT相对MRI和CT均为最具成本效果的策略,MRI相对CT为具有成本效果的策略。
  • 确定性和概率敏感性分析显示模型稳健性高,在输入参数广泛变异范围内增量成本效果比保持在100,000美元/QALY以下。

关键数值与推荐

  • 支付意愿阈值设定为100,000美元/QALY。
  • 基础方案总成本:CT 239,628美元,MRI 240,001美元,F-18 FDG PET/CT 239,131美元。
  • 基础方案效果:CT 5.29 QALYs,MRI 5.30 QALYs,F-18 FDG PET/CT 5.32 QALYs。
  • 敏感度分析中增量成本效果比保持在100,000美元/QALY以下。

临床怎么用

  • 作者认为,基于这些发现,可建议在口腔鳞状细胞癌初始分期中实施PET/CT,以帮助降低成本并提高效果。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: Treatment of oral squamous cell carcinoma (OSCC) is based on clinical exam, biopsy, and a precise imaging-based TNM-evaluation. A high sensitivity and specificity for magnetic resonance imaging (MRI) and F-18 FDG PET/CT are reported for N-staging. Nevertheless, staging of oral squamous cell carcinoma is most often based on computed tomography (CT) scans. This study aims to evaluate cost-effectiveness of MRI and PET/CT compared to standard of care imaging in initial staging of OSCC within the US Healthcare System. METHODS: A decision model was constructed using quality-adjusted life years (QALYs) and overall costs of different imaging strategies including a CT of the head, neck, and the thorax, MRI of the neck with CT of the thorax, and whole body F-18 FDG PET/CT using Markov transition simulations for different disease states. Input parameters were derived from literature and willingness to pay (WTP) was set to US $100,000/QALY. Deterministic sensitivity analysis of diagnostic parameters and costs was performed. Monte Carlo modeling was used for probabilistic sensitivity analysis. RESULTS: In the base-case scenario, total costs were at US $239,628 for CT, US $240,001 for MRI, and US $239,131 for F-18 FDG PET/CT whereas the model yielded an effectiveness of 5.29 QALYs for CT, 5.30 QALYs for MRI, and 5.32 QALYs for F-18 FDG PET/CT respectively. F-18 FDG PET/CT was the most cost-effective strategy over MRI as well as CT, and MRI was the cost-effective strategy over CT. Deterministic and probabilistic sensitivity analysis showed high robustness of the model with incremental cost effectiveness ratio remaining below US $100,000/QALY for a wide range of variability of input parameters. CONCLUSION: F-18 FDG PET/CT is the most cost-effective strategy in the initial N-staging of OSCC when compared to MRI and CT. Despite less routine use, both whole body PET/CT and MRI are cost-effective modalities in the N-staging of OSCC. Based on these findings, the implementation of PET/CT for initial staging could be suggested to help reduce costs while increasing effectiveness in OSCC.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Burian E, Palla B, Callahan N, et al. Comparison of CT, MRI, and F-18 FDG PET/CT for initial N-staging of oral squamous cell carcinoma: a cost-effectiveness analysis. Eur J Nucl Med Mol Imaging. 2022. PMID: 35606526. doi:10.1007/s00259-022-05843-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。